Senior insider sale
CEO at EAGLE PHARMACEUTICALS, INC. — senior position signals high conviction
$450.0K
31.17K shares
What this filing means
TARRIFF SCOTT plans to sell 31.17K shares of EAGLE PHARMACEUTICALS, INC. valued at approximately $450.0K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 11/1/2023ACC: 0001972649-23-000005
DirectorOfficer· CEO
Since Jun 2018
31.17K
Shares to sell
$450.0K
Approx. market value
10.93K
Acquired (3 months)
1
Planned
3 completed
Securities Acquired — Last 3 Months3
Executive Compensation
Cash
2/28/2022
5.59KExecutive Compensation
Cash
4/1/2021
296.00Executive Compensation
Cash
1/5/2020
5.04KTotal acquired10.93K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/28/2022 | Executive Compensation Cash | 5.59K | — |
4/1/2021 | Executive Compensation Cash | 296.00 | — |
1/5/2020 | Executive Compensation Cash | 5.04K | — |
| Total | 10.93K | ||
Planned & Completed Dispositions4
Completed
—Completed
Units to sell
9.68K
Market value
$140.0K
10/3/2023
—Completed
Units to sell
1.05K
Market value
$15.2K
10/3/2023
—Completed
Units to sell
9.51K
Market value
$144.9K
10/2/2023
Planned — Approximate Date
NASDAQPlanned
Units to sell
10.93K
Market value
$150.0K
11/1/2023
Total
Units
31.17K
Value
$450.0K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
10/3/2023 | 9.68K | $140.0K | — | Completed |
10/3/2023 | 1.05K | $15.2K | — | Completed |
10/2/2023 | 9.51K | $144.9K | — | Completed |
| Planned — Approximate Date | ||||
11/1/2023 | 10.93K | $150.0K | NASDAQ | Planned |
| Total | 31.17K | $450.0K | ||